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P U B L I S H E D B Y E L S E V I E R I N C .LettersShort Versus Long
Duration of DAPT
After DES Implantation:
A Meta-AnalysisThe optimal duration of dual antiplatelet therapy
(DAPT) after percutaneous coronary intervention
(PCI) with drug-eluting stents (DES) has not been
determined. Current American College of Cardiology
Foundation/American Heart Association (ACCF/AHA)
guidelines recommend 12-month DAPT on the basis of
observational evidence suggesting an increased risk
of stent thrombosis after premature cessation of DAPT
(1). We performed a meta-analysis of randomized
trials comparing short-term DAPT (#6 months)
with ACCF/AHA guideline–recommended duration
of DAPT (at least 12 months) among patients
undergoing PCI with DES.
In March 2014, we searched PubMed, EMBASE,
and Cochrane Clinical Trials for published random-
ized trials directly comparing short-term DAPT
(#6months) with ACCF/AHA guideline–recommended
DAPT (at least 12 months) after PCI with DES. Risk
ratios (RRs) were applied as the metric of choice for
treatment effects using random- and ﬁxed-effects
models. I-square index was used to assess heteroge-
neity across trials. The primary safety and efﬁcacy
outcomes were any bleeding and the composite
of cardiac death and myocardial infarction (MI),
respectively. The secondary efﬁcacy outcome was
deﬁnite or probable stent thrombosis. Meta-analyses
were performed using Stata software (StataCorp,
College Station, Texas).
Four eligible trials were identiﬁed that included
8,649 patients with at least 12 months of follow-
up: EXCELLENT (Efﬁcacy of Xience/Promus Versus
Cypher to Reduce Late Loss After Stenting) (2),
PRODIGY (PROlonging Dual Antiplatelet Treatment
In Patients With Coronary Artery Disease After
Graded Stent-induced Intimal Hyperplasia study)
(3), RESET (REal Safety and Efﬁcacy of 3-month
dual antiplatelet Therapy following Endeavor
zotarolimus-eluting stent implantation) (4), andOPTIMIZE (Optimized Duration of Clopidogrel
Therapy Following Treatment With the Endeavor
Zotarolimus-Eluting Stent in Real World Clinical
Practice) (5). Results are presented in Figure 1.
Short-term DAPT was associated with a reduced
risk of any bleeding as compared with guideline-
recommended DAPT (RR: 0.64; 95% conﬁdence
interval: 0.46 to 0.89). Risks of cardiac death or MI
(RR: 1.08; 95% conﬁdence interval: 0.89 to 1.32)
and stent thrombosis (RR: 1.24; 95% conﬁdence
interval: 0.76 to 2.02) did not differ between short-
term DAPT and guideline-recommended DAPT.
There was no signiﬁcant heterogeneity across trials
for the analyzed outcomes.
Little evidence is available on the optimal duration
of DAPT after DES implantation. Pivotal DES trials
applied short-term DAPT (2 to 6 months). However,
in 2006, observational ﬁndings from more complex
patient populations revealed an increased risk of
stent thrombosis after premature discontinuation
of DAPT. The U.S. Food and Drug Administration
convened an expert advisory board meeting to
address the safety issues surrounding use of DES,
which led to the implementation of at least a
12-month duration of DAPT after DES implanta-
tion in the ACCF/AHA guidelines (1). Since that time,
several randomized trials have investigated different
durations of DAPT. In our meta-analysis, we included
trials directly comparing short-term with ACCF/
AHA guideline–recommended DAPT, all of which
were powered for composite clinical endpoints.
We provide evidence of a signiﬁcant bleeding risk
reduction with short-term DAPT compared with
ACCF/AHA guideline–recommended DAPT after DES
implantation. The reduced risk of bleeding was
paralleled by similar risks of cardiac death or MI as
well as stent thrombosis with the 2 DAPT regimens,
suggesting that short-term DAPT is associated with
a safety beneﬁt while preserving antithrombotic
efﬁcacy. The ongoing ISAR-SAFE (Intracoronary
Stenting and Antithrombotic Regimen: Safety And
EFﬁcacy of Six Months Dual Antiplatelet Therapy
After Drug-Eluting Stenting) trial plans inclusion of
6,000 patients to test noninferiority of 6-month
DAPT compared with 12-month DAPT for the
composite endpoint of death, MI, stent thrombosis,
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FIGURE 1 Clinical Outcomes With Short (#6 Months) Versus Standard
(At Least 12 Months) DAPT
The extracted number of events was based on intention-to-treat analysis in each
study. The composite of all-cause death or MI was extracted for the EXCELLENT
and PRODIGY trials, because the composite of cardiac death or MI was not re-
ported. CI ¼ conﬁdence interval; DAPT ¼ dual antiplatelet therapy; EXCELLENT ¼
Efﬁcacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting;
FEM ¼ ﬁxed-effects models; MI ¼ myocardial infarction; PRODIGY ¼ PROlonging
Dual Antiplatelet Treatment In Patients With Coronary Artery Disease After Graded
Stent-induced Intimal Hyperplasia study; REM ¼ random-effects models; RR ¼ risk
ratio.
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954stroke, or bleeding, assuming an event rate of
10% and specifying a noninferiority margin of 1.2,
with 80% power and an alpha level of 0.05
(NCT00661206).
This meta-analysis needs to be interpreted in
light of the following limitations. First, ﬁndings
need to be considered average effects because we
did not have access to patient-level data; as such,
they may not apply across speciﬁc subgroups. Sec-
ond, short-term DAPT regimens varied between
the included trials. The optimal duration of short-
term DAPT will need to be investigated in future
studies. Third, different DES were used in the in-
cluded trials and results may vary according to DES
type. Finally, our ﬁndings are limited to clopidogrel
and may differ with the use of newer P2Y12
inhibitors.
In conclusion, this meta-analysis indicates that
short-term DAPT is associated with a reduced riskof bleeding but preserved antithrombotic efﬁcacy
compared with guideline-recommended 12-month
DAPT after DES implantation. These hypothesis-
generating ﬁndings need to be conﬁrmed by
adequately powered randomized trials.Giulio G. Stefanini, MDy
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